6N0P

BRAF in complex with N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)

6N0P の概要

• エントリーDOI: 10.2210/pdb6n0p/pdb
• 分子名称: Serine/threonine-protein kinase B-raf, N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide (3 entities in total)
• 機能のキーワード: raf, braf, craf, craf kinase, serine threonine protein, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 63283.23

構造登録者

Mamo, M.,Appleton, B.A. (登録日: 2018-11-07, 公開日: 2019-09-04, 最終更新日: 2024-03-13)

主引用文献

Ramurthy, S.,Taft, B.R.,Aversa, R.J.,Barsanti, P.A.,Burger, M.T.,Lou, Y.,Nishiguchi, G.A.,Rico, A.,Setti, L.,Smith, A.,Subramanian, S.,Tamez, V.,Tanner, H.,Wan, L.,Hu, C.,Appleton, B.A.,Mamo, M.,Tandeske, L.,Tellew, J.E.,Huang, S.,Yue, Q.,Chaudhary, A.,Tian, H.,Iyer, R.,Hassan, A.Q.,Mathews Griner, L.A.,La Bonte, L.R.,Cooke, V.G.,Van Abbema, A.,Merritt, H.,Gampa, K.,Feng, F.,Yuan, J.,Mishina, Y.,Wang, Y.,Haling, J.R.,Vaziri, S.,Hekmat-Nejad, M.,Polyakov, V.,Zang, R.,Sethuraman, V.,Amiri, P.,Singh, M.,Sellers, W.R.,Lees, E.,Shao, W.,Dillon, M.P.,Stuart, D.D.
Design and Discovery ofN-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
J.Med.Chem., 63:2013-2027, 2020

PubMed Abstract: Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, (RAF709; Nishiguchi, G. A.; et al. , , 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of . Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.

PubMed: 31059256
DOI: 10.1021/acs.jmedchem.9b00161

実験手法

X-RAY DIFFRACTION (2.37 Å)